Markets

Insider Trading

Hedge Funds

Retirement

Opinion

The Most Advanced Country in Biomedical Engineering

We recently compiled a list of the 15 Most Advanced Countries in Biomedical Engineering and in this article, we will talk about the most advanced country in biomedical engineering.

The biotechnology global market size was estimated at $1.38 trillion in 2023 and is expected to reach around $4.25 trillion by 2033 while growing at a CAGR of 11.8%. North America led the market with a 37.79% revenue share in 2023 owing to the strong R&D initiatives and high healthcare expenses. Meanwhile, the Asia-Pacific region is anticipated to grow at the fastest rate, with a CAGR of over 12.7% during the forecast period, due to improved healthcare infrastructure and supportive government regulations.

The bio-pharmacy segment, which captured 41.73% of the revenue share in 2023, is a major driver due to the increasing demand for medicines and drugs. Additionally, tissue engineering and regeneration technologies, which dominated the market by technology with a 19.26% share, are expanding tremendously in different healthcare domains.

In 2023 alone, the FDA approved 53 new drugs, with over 60% originating from biotech firms. The adoption of CRISPR technology for gene editing and the development of monoclonal antibodies for targeted therapies have only confirmed the sector’s potential. Additionally, the integration of artificial intelligence (AI) in biotechnology is speeding up research and development processes in the industry.

However, despite these developments, the biotechnology industry is facing some challenges. According to the EY Biotechnology Report 2024, there is a mixed landscape where only companies with strong clinical data or nearly marketed assets can attract high investments. In 2023, venture capital funding for biotech startups dropped by 28%.

Before getting into biomedical engineering as a profession and its developments around the world, let’s look at the key players in the biotech market.

Amgen Inc (NASDAQ:AMGN) reported nearly $26 billion in revenue in 2022 which is attributed largely to its diverse portfolio of treatments. Amgen Inc (NASDAQ:AMGN)’s flagship products, including the osteoporosis drug Prolia and the cholesterol-lowering Repatha, have collectively brought in billions.

One of Amgen Inc (NASDAQ:AMGN)’s major victories was the development and marketing of sotorasib, branded as Lumakras, which targets the KRAS G12C mutation in lung cancer. Since its launch in 2021, Lumakras has provided major benefits to patients like Don Crosslin, despite its high toxicity and $20,000 monthly cost. In 2023, Lumakras generated nearly $200 million in US sales.

On the other hand, Moderna Inc (NASDAQ:MRNA) has received $176 million in federal funding to develop mRNA vaccines against the H5N1 bird flu virus. This funding will support the late-stage development of an mRNA-based vaccine designed to fight the highly contagious H5N1 influenza virus, which has been causing alarm as it spreads among animals and occasionally infects humans.

Since 2023, Moderna Inc (NASDAQ:MRNA) has been conducting early-stage clinical trials for mRNA pandemic flu vaccines to target the H5 and H7 strains known for their potential to become highly virulent. Results from these trials are expected in 2024 and will guide the late-stage development of the vaccine. The newly formed Rapid Response Partnership Vehicle (RRPV) is funding Moderna Inc (NASDAQ:MRNA)’s project along with other initiatives to address emerging infectious diseases and biological threats.

Apart from the developed countries, some developing economies like India have been at the forefront of research and innovation in biomedical engineering. For example, according to the Scimago Institution Ranking, there are 120 top biomedical engineering research institutions in India. However, since the salaries in India are relatively far less than the ones offered in developed countries, India didn’t make it to our list of the most advanced countries in biomedical engineering.

When looking for biomedical engineering jobs abroad, professionals can find roles in the research, development, and implementation of medical devices, prosthetics, and diagnostic equipment. Countries with strong healthcare sectors, such as the USA, Germany, and Singapore, often have a high demand for biomedical engineers.

A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds.

Is the United States the Most Advanced Country in Biomedical Engineering?

To identify the most advanced countries in biomedical engineering, we utilized the Scimago Institution Rankings with a focus on research and innovation output and also analyzed the average salaries of biomedical engineers globally. We selected the top 25 countries with the highest number of leading institutions in biomedical engineering and the top 30 countries with the highest average salaries for biomedical engineers. Each country was then ranked within these two categories, with a rank of 1 representing the highest number of top institutions and the highest average salary, respectively.

The rationale for using the metric of high average salaries was that it gave us countries with thriving biomedical-engineering markets, which indirectly shows these countries are not only advancing technologically in the field, they’re also likely attracting talent from across the world.

Next, we calculated the average rank for each country by combining its rank in research and innovation with its rank in average salary. This provided us with an average composite score. In cases where countries had identical average ranks, the country with the higher rank in research and innovation was ranked higher. The list is presented in ascending order (from low to high rank).

Our methodology puts the US on top of the list for countries that are the most advanced in biomedical engineering. In 2021, venture financing for US-headquartered biotech firms reached a peak of $20.7 billion with a 104% increase from the previous year. This increase in funding facilitated numerous early-stage biotechs going public with high valuations. The National Institutes of Health (NIH) also reported a 16.1% increase in grant funding from 2021 to 2022.

The profession of a biomedical engineer in the US generally requires a bachelor’s degree in bioengineering or a related field, though some roles may require advanced degrees. The job market is stable with about 19,700 positions reported in 2022 and an anticipated growth rate of 5% from 2022 to 2032. According to the Scimago Institution Ranking, there are 336 top biomedical engineering institutions in the US. The average salary of a biomedical engineer in the country is $112,525, making it one of the top-paying countries for biomedical engineers.

To check out the extensive list of biomedical engineering countries which are advanced, please visit 15 Most Advanced Countries in Biomedical Engineering.

At Insider Monkey, we delve into a variety of topics, ranging from passive income ideas to business aspects; however, our expertise lies in identifying the top-performing stocks. Currently, Artificial Intelligence (AI) technology stands out as one of the most promising fields. If you are looking for an AI stock that is more promising than NVDA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: Michael Burry Is Selling These Stocks and Jim Cramer is Recommending These Stocks.

Disclosure: None. 15 Most Advanced Countries in Biomedical Engineering is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…